GlassScriptPhysician profile
Saifuddin Soniwala
NPI 1982620027
$1,333.96
in general payments reported to CMS, 2019-2025
14 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $495 · 2021: $11.92 · 2023: $189 · 2024: $197 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $589.23 | 2020-2025 | |
| Myriad Genetic Laboratories, INC. | $137.86 | 2023 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $125.01 | 2019 | |
| Astellas Pharma US INC | $99.95 | 2020 | |
| Pfizer INC. | $82.72 | 2025 | |
| Daiichi Sankyo INC. | $51.56 | 2023 | Enhertu |
| Abbvie INC. | $51.24 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.01 | 2020-2024 | Fruzaqla |
| Celgene Corporation | $41.11 | 2025 | Reblozyl |
| Genzyme Corporation | $35.91 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $27.25 | 2020-2024 | Reblozyl |
| Incyte Corporation | $18.39 | 2020 | |
| Array Biopharma INC | $15.80 | 2024 | Tukysa, Braftovi, Mektovi |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saifuddin Soniwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.